A team of scientists at The Institute of Cancer Research in London and The Royal Marsden NHS Foundation Trust have developed a blood test which could analyse whether a breast cancer patient is responding to the treatment palbociclib in two to three weeks, potentially reaching a judgement months earlier than current testing allows.

Bron: Pharmafile | lees verder..